Document is current
Any future updates will be listed below
-
Authors
Harel, Michal
Lahav, Coren
Jacob, Eyal
Dahan, Nili
Sela, Itamar
Elon, Yehonatan
Raveh Shoval, Shani
Yahalom, Galit
Kamer, Iris
Zer, Alona
Sharon, Ofer
Carbone, David P
Dicker, Adam P
Bar, Jair
Shaked, Yuval https://orcid.org/0000-0001-9037-3895
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04148937 at ClinicalTrials.govnct02860546 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
https://doi.org/10.1136/jitc-2023-006842
Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma
https://doi.org/10.1136/jitc-2020-001467
nct02848443 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
nct03475953 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
nct04591431 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.
https://doi.org/10.1200/jco.2024.42.16_suppl.11516
1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and REGONIVO studies
https://doi.org/10.1136/jitc-2023-sitc2023.1521
nct02646748 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group
https://doi.org/10.1136/ijgc-2022-003425
Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.3157
nct03334617 at ClinicalTrials.govDocuments that mention this clinical trial
Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
https://doi.org/10.1136/jitc-2020-000693
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA
https://doi.org/10.1136/jitc-2020-001037
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
nct02983578 at ClinicalTrials.govDocuments that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
https://doi.org/10.1136/jitc-2023-sitc2023.0695
nct03819465 at ClinicalTrials.govDocuments that mention this clinical trial
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer
https://doi.org/10.1136/bmjonc-2023-000133
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
Documents that mention this clinical trial
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
https://doi.org/10.1136/jitc-2022-004582
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors
https://doi.org/10.1136/bmjonc-2025-001037
- License Information
